Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

TRNA m1A modification enhances anti-tumor immunity in macrophages by promoting translation of key interferon associated genes [BMDMs bulk RNA-seq]

ABSTRACT: The involvement of tRNA m1A modification in the anti-tumoral tumor-associated macrophages (TAMs) has been validated in our study that macrophage-specific knockout of m1A “writer” enzymes TRMT61A leads to increased infiltration of TAMs, impaired CD8+ T cell function, and enhanced tumor growth. Since TRMT61A-derived tRNA m1A modification mainly enhances translation efficiency, we reasoned that the loss of TRMT61A in macrophages would result in the downregulation of a group of protein levels without affecting their mRNA levels. To assess the impact of TRMT61A deficiency on mRNA transcript levels in macrophages, we collected TRMT61A-KO and WT BMDMs derived from Trmt61af/fLysmCre and Trmt61af/f mice to perform bulk RNA sequencing. Of total 22173 genes, the mRNA expression of 22054 genes remain unchanged in macrophages upon TRMT61A deletion, suggesting that TRMT61A did not contribute to mRNA transcriptional regulation in macrophages.

ORGANISM(S): Mus musculus

PROVIDER: GSE239601 | GEO | 2026/03/04

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

tRNA m1A modification enhances anti-tumor immunity in macrophages by promoting translation of key interferon associated genes [TAMs bulk RNA-seq]

Project description:Tumor-associated macrophages (TAMs) play a crucial role in tumor progression through their recruitment, polarization, and interaction with T cells in the tumor microenvironment (TME). However, the mechanisms underlying the post-transcriptional and translational regulation of TAMs in the TME remain largely unknown. In this study, we investigate the role of tRNA N1-methyladenosine (m1A) modification in controlling the behavior of macrophages in response to TME stimuli. We demonstrate that the m1A “writer” enzymes TRMT61A is highly enriched in the anti-tumoral and phagocytotic TAM subset, and TRMT61A is rapidly downregulated in macrophages upon stimulation with multiple TME components. Macrophage-specific knockout of TRMT61A leads to increased infiltration of TAMs, impaired CD8+ T cell function, and enhanced tumor growth. To further explore the biological effects of m1A deficient macrophages, we performed RNA sequencing analysis of TRMT61A-KO and WT TAMs derived from tumor bearing Trmt61af/fLysmCre and Trmt61af/f mice. The Gene ontology (GO) and Gene set enrichment analysis (GSEA) documented that the interferon response and the STAT1/IL-12 signaling pathway were impaired in TAMs upon TRMT61A deletion, indicating that TRMT61A is critical for macrophages to control interferon responses and exert anti-tumor effect in the TME.

2026-03-04 | GSE239606 | GEO

tRNA m1A modification in macrophages promotes translation of interferon pathway genes to enhance CD8+ T cell-mediated anti-tumor immunity [CAR-iMACs RNA-seq]

Project description:The involvement of tRNA m1A modification in the anti-tumoral tumor-associated macrophages (TAMs) has been validated in our study that macrophage-specific knockout of m1A “writer” enzymes TRMT61A leads to increased infiltration of TAMs, impaired CD8+ T cell function, and enhanced tumor growth. Since we observed that tumor-derived components suppresses tRNA m1A modification in macrophages, we sought to identify which component in the TME induces the down-regulation of tRNA m1A modification. Here, we performed bulk RNA-seq using TRMT61AOE-CAR-iMACs and CAR-iMACs to ensure the effect of human Trmt61a overexpression on CAR-iMACs. Kyoto encyclopedia of genes and genomes (KEGG) analysis showed that signal transduction is the most up-regulated pathway in CAR-iMACs after human Trmt61a overexpression.

2026-03-04 | GSE288142 | GEO

m1A inhibition fuels oncolytic virus-elicited antitumor immunity via downregulating PD-L1 expression

Project description:RNA N1-methyladenosine methylation (m1A) modification is critical in regulating mRNA translation and thus protein synthesis, but the role of m1A modification in the occurrence, progression, and immunotherapy of head and neck squamous cell cancer (HNSCC) remains largely unknown. In Tgfbr1/Pten 2cKO mice, we found that the spontaneous neoplastic transformation of oral mucosa is accompanied by elevated levels of m1A modification. Analysis of m1A-associated genes identified TRMT61A as the key m1A writer associated with cancer progression, and poor prognosis. Mechanically, TRMT61A-induced tRNA-m1A modification promotes MYC protein synthesis and subsequent programmed death-ligand 1 (PD-L1) expression. In Tgfbr1/Pten 2cKO mice, RNA-m1A modification levels are also elevated in tumors that developed resistance to oncolytic herpes simplex virus (oHSV) treatment. Therapeutic inhibition of m1A modification sustains oncolytic virus-induced antitumor immunity and reduces tumor growth, providing a promising strategy for alleviating resistance to oHSV therapy. These findings indicate that m1A inhibition can prevent immune escape after oHSV therapy by reducing the expression of PD-L1. Our results provide a mutually reinforcing strategy for clinical combination immunotherapy.

2024-03-31 | GSE247024 | GEO

tRNA m1A modification regulates cholesterol biosynthesis to promote antitumor immunity of CD8+ T cells

Project description:Activation of CD8+ T cells necessitates rapid metabolic reprogramming to fulfill the substantial biosynthetic demands of their effector functions. However, the post-transcriptional mechanisms underpinning this process remain obscure. The tRNA N1-methyladenine (m1A) modification, which plays a role in maintaining tRNA stability and modulating protein translation, has an undefined physiological function in CD8+ T cells, particularly in antitumor responses. Here, we demonstrate that the tRNA m1A 'writer' gene Trmt61a enhances the tumor-killing capacity of CD8+ T cells by regulating cholesterol biosynthesis. We find that Trmt61a expression in CD8+ T cells is upregulated upon activation and correlates positively with T cell-mediated cytotoxicity within the tumor microenvironment of colorectal cancer (CRC) patients. Deletion of Trmt61a in CD8+ T cells leads to a compromised tumor-killing function in both in vivo and in vitro assays, which is dependent on the m1A catalytic activity of TRMT61A. Mechanistically, tRNA m1A promotes antitumor immunity in CD8+ T cells by enhancing the translation of ATP citrate lyase (ACLY), a key enzyme for cholesterol biosynthesis. Supplementation with cholesterol can rescue the impaired tumor-killing function and proliferation of TRMT61A-deficient CD8+ T cells. Our findings underscore the significance of tRNA m1A modification as a regulatory checkpoint in cholesterol metabolism in CD8+ T cells, suggesting potential novel strategies for cancer immunotherapy.

2025-01-07 | GSE275602 | GEO

Chemical manipulation of m1A mediates its detection in human tRNA

Project description:N1-methyl adenosine (m1A) is a wide-spread RNA modification present in tRNA, rRNA and mRNA. m1A modification sites in tRNAs are evolutionary conserved and its formation on tRNA is catalyzed by methyltransferase TRMT61A and TRMT6 complex. m1A promotes translation initiation and elongation. Due to its positive charge under physiological conditions, m1A can notably modulate RNA structure. It also blocks Watson-Crick base pairing and causes mutation and truncation during reverse transcription. Several misincorporation-based high throughput sequencing methods have been developed to sequence m1A. In this study, we introduce a reduction-based m1A sequencing (red-m1A-seq). We report that NaBH4 reduction of m1A can improve the mutation and readthrough rates using commercially available RT enzymes to give better positive signature, while alkaline-catalyzed Dimroth rearrangement can efficiently convert m1A to m6A to provide good controls, allowing the detection of m1A with higher sensitivity and accuracy. We applied red‑m1A-seq to sequence human small RNA and we not only detected all the previously reported tRNA m1A sites, but also new m1A sites in mt-tRNAAsn-ATT and 5.8S rRNA.

2024-04-24 | GSE253657 | GEO

tRNA m1A modification is essential for gut homeostasis and function of group 3 innate lymphoid cells

Project description:Group 3 innate lymphoid cells (ILC3s) play crucial roles in maintaining intestinal homeostasis and defending against bacterial infections. However, the epigenetic mechanisms that regulate ILC3 responses are not well understood. In this study, we show that Trmt61a, the methyltransferase responsible for the m1A58 tRNA modification, is predominantly expressed in ILC3s. We found that specific depletion of TRMT61A in ILC3s leads to dysregulated cell cycle and a reduction in cell numbers. Notably, mice with an ILC3-specific TRMT61A deficiency exhibit dysbiosis, but antibiotic treatment can restore colonic ILC3 levels. Furthermore, these mice exhibit increased susceptibility to experimental intestinal inflammation and enteric bacterial infection. Our findings uncover a previously unrecognized role for TRMT61A mediated m1A modification in the regulation of intestinal ILC3s, essential for protecting intestinal tissue during inflammation and enhancing innate immunity against enteric pathogens.

2025-10-11 | GSE267755 | GEO

RNA m1A methyltransferase TRMT61A induces MAPK/ERK signaling and is a therapeutic target in colorectal cancer I

Project description:The role of N1-methyladenosine (m1A) in cancer remains poorly understood. Here we investigate the functional importance of RNA m1A methyltransferase TRMT61A in colorectal cancer (CRC) and assess its potential as a therapeutic target. Our findings demonstrate consistent elevation of TRMT61A expression and RNA m1A levels in primary CRC tissues, which correlate significantly with poor patient survival. Through CRISPR/Cas9 screenings, TRMT61A is the most essential gene among m1A regulators. We further elucidate that TRMT61A facilitates CRC tumorigenesis and progression by enhancing the stability of mRNA of crucial targets, including ONECUT2, thereby activating the MAPK/ERK signaling pathway in an m1A-dependent manner. Of note, we show promising anti-CRC effects by inhibiting TRMT61A using nanoparticleencapsulated siTRMT61A or our identified small molecule compound, PGG. Collectively, our study uncovers the essential role of TRMT61A-m1A in CRC by activating the ONECUT2-MAPK/ERK pathway. Targeting TRMT61A holds promise as a therapeutic approach for treating CRC.

2025-02-01 | GSE274027 | GEO

RNA m1A methyltransferase TRMT61A induces MAPK/ERK signaling and is a therapeutic target in colorectal cancer II

2025-02-01 | GSE274028 | GEO